American Journal of Cardiology
Volume 104, Issue 4 , Pages 507-513, 15 August 2009

Prevalence, Predictors, and In-Hospital Outcomes of Non-Infarct Artery Intervention During Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (from the National Cardiovascular Data Registry)

  • Matthew A. Cavender, MD

      Affiliations

    • Department of Medicine, Duke University Medical Center, Durham, North Carolina
    • Corresponding Author InformationCorresponding author: Tel: (919) 684-8111; fax: (919) 681-6448
  • ,
  • Sarah Milford-Beland, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina
  • ,
  • Matthew T. Roe, MD, MHS

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina
  • ,
  • Eric D. Peterson, MD, MPH

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina
  • ,
  • William S. Weintraub, MD

      Affiliations

    • Christiana Care Health System, Newark, Delaware
  • ,
  • Sunil V. Rao, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina

Received 20 February 2009; received in revised form 2 April 2009; accepted 2 April 2009. published online 22 June 2009.

Guidelines support percutaneous coronary intervention (PCI) of the noninfarct-related artery during primary PCI for ST-segment elevation myocardial infarction (STEMI) in patients with hemodynamic compromise; however, in patients without hemodynamic compromise, PCI of the noninfarct-related artery is given a class III recommendation. We analyzed the National Cardiovascular Data Registry (n = 708,481 admissions, 638 sites) to determine the prevalence, predictors, and in-hospital outcomes of primary multivessel PCI from 2004 to 2007. Patients with STEMI and multivessel coronary artery disease who were undergoing primary PCI were identified (n = 31,681). After excluding the patients treated with staged PCI (n = 2,745), 10.8% (n = 3,134) of the remaining population (n = 28,936) were treated with multivessel PCI. Patients undergoing multivessel PCI were at higher risk and were more likely to be in cardiogenic shock. The overall in-hospital mortality rates were greater in patients undergoing multivessel PCI (7.9% vs 5.1%, p <0.01). Among patients with STEMI and cardiogenic shock (n = 3,087), those receiving multivessel PCI had greater in-hospital mortality (36.5% vs 27.8%; adjusted odds ratio 1.54, 95% confidence interval 1.22 to 1.95). In conclusion, these data suggest that performing multivessel PCI during primary PCI for STEMI does not improve short-term survival even for patients with cardiogenic shock. These findings suggest the need for definitive studies to evaluate the utility of noninfarct-related artery PCI among patients with STEMI.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This analysis was supported by a grant from the American College of Cardiology, Washington, DC, and the Society for Cardiac Angiography and Interventions, Washington, DC.

 This analysis was supported by the National Cardiovascular Data Registry.

 Dr. Roe was supported by research grants from Schering Plough, BMS/Sanofi-Aventis, KAI Pharmaceuticals, and DeCODE Genetics; is on the consulting/advisory boards for Schering Plough, KAI Pharmaceuticals; and is on the Speakers Bureau or has received honoraria from Schering Plough and BMS/Sanofi-Aventis.

 Dr. Peterson has received research grants from Bristol-Myers Squibb, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Bristol-Myers Squibb/Merck, and Schering (additional disclosure information for Dr. Peterson is available from: http://dcri.org/research/coi.jsp).

 Dr. Rao is a Consultant for Sanofi-Aventis and member of the Speakers' Bureaus for Sanofi-Aventis, Bristol Myers Squibb, and the Medicines Company and has received research funding from Momenta Pharmaceuticals, Portola Pharmaceuticals, and Cordis.

PII: S0002-9149(09)00919-9

doi:10.1016/j.amjcard.2009.04.016

American Journal of Cardiology
Volume 104, Issue 4 , Pages 507-513, 15 August 2009